secwatch.observer — SEC 8-K summary
======================================

Issuer:     KALA BIO, Inc. (KALA)
CIK:        0001479419
Form:       8-K
Filed at:   2022-11-08T23:59:59+00:00
Accession:  0001558370-22-016752
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kala Pharma reports $52.4M cash; plans Phase 2/3 trial for KPI-012 in Q4 2022 with data 1Q 2024
--------------------------------------------------------------------------------

- Cash and equivalents of $52.4M as of Sept 30, 2022, expected to fund operations into Q2 2024.
- Plans to initiate Phase 2/3 trial of KPI-012 for PCED in Q4 2022; topline data expected Q1 2024.
- Appointed Marjan Farid, M.D., to Board of Directors in November 2022.
- Effected 1-for-50 reverse stock split on October 20, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1479419/000155837022016752/0001558370-22-016752-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1479419/000155837022016752/kala-20221108x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-016752

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer